Latest News and Press Releases

Alumis to participate in two upcoming November investor conferences: Guggenheim’s 2nd Annual Healthcare Innovation Conf and the Stifel 2025 Healthcare Conf

EXTON, PA, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Sjögren’s Disease (SjD) continues to present significant diagnostic and therapeutic challenges within rheumatology, according to Spherix Global Insights’...

Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis

Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025

Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in 1Q 2026

Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases

Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company.

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO...